Skip to main content
. 2021 Feb 24;16(2):e0246601. doi: 10.1371/journal.pone.0246601

Fig 4. Analysis and comparison of plasma PAIC’s across time in ApoE-/-, with SCI, and Salsalate.

Fig 4

A. IL-1β in ApoE-/-SCI is significantly greater than time-controlled groups at 28-weeks and compared to all groups at previous timepoints (*). No other between group difference are observed. B. IL-6 is significantly greater in all groups at 28-weeks and in ApoE-/-SCI at 24-weeks compared to all groups at 16- and 20-weeks (*). At 24-weeks, IL-6 in ApoE-/-SCI is significantly greater than time-controlled groups, and no other time-controlled differences are observed. At 24- and 28-weeks, IL-6 in ApoE-/-SCI is significantly greater compared to ApoE-/-SCI at 20-weeks (*). C. TNFα is significantly increased in all groups at 28-weeks compared to ApoE-/- at 16- and 20-weeks (*). At 28-weeks, TNFα in ApoE-/-SCI but not ApoE-/- is significantly greater than in ApoE-/- at 24-weeks and ApoE-/-SCI at 20-weeks (*). D. MCP-1 is significantly greater in all groups at 28-weeks compared to ApoE-/- at all previous timepoints (*). At 24- and 28-weeks, MCP-1 in ApoE-/-SCI is significantly greater than in ApoE-/-SCI at 20-weeks (*) as well as time-controlled ApoE-/- and Salsalate treatment (ApoE-/-SCI/sal, ^†). E. CCL-5 is significantly greater in all groups at 28-weeks compared to ApoE-/- at 16- and 20-weeks (*). At 28-weeks, CCL-5 in ApoE-/-SCI is significantly greater than in ApoE-/-SCI at previous timepoints (*) and both inury groups (ApoE-/-SCI and ApoE-/-SCI/sal) are significantly greater than ApoE-/- (^). *^*^†p < 0.05.